Related Experiment Video
Updated: Feb 8, 2026

JenaTron - An Experimental Approach to Study the Effects of Plant History and Soil History on Grassland Ecosystem Functioning
Published on: March 21, 2025
Hypertension: history and development of established and novel treatments
Milan Wolf1, Sebastian Ewen1, Felix Mahfoud1
1Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Universität des Saarlandes, Angiologie und Internistische Intensivmedizin, Kirrberger Str. 1, 66421, Homburg, Saar, Germany.
Insights
Hypertension management has evolved significantly, from an undefined condition to a key modifiable cardiovascular risk factor. Ongoing research focuses on novel drug and device therapies to further reduce cardiovascular events.
Area of Science:
- Cardiology
- Vascular Medicine
- Pharmacology
Background:
- Hypertension (high blood pressure) has transitioned from an ill-defined condition to a primary modifiable cardiovascular risk factor.
- Significant advancements in drug and interventional treatments have been made over recent decades.
- The evolving understanding of hypertension impacts cardiovascular outcome strategies.
Purpose of the Study:
- To summarize the historical development and paradigm shifts in the field of hypertension.
- To review the evolution of drug and interventional treatments for hypertension.
- To discuss current and future therapeutic strategies for improving cardiovascular outcomes in hypertensive patients.
Main Methods:
- A selective literature search was conducted in PubMed.
- The search included trials published up to 2018 without time restrictions.
- Unpublished trials from ClinicalTrials.gov were also incorporated.
Main Results:
- Hypertension treatment has progressed significantly, marked by the development of effective and tolerable medications.
- Interventional techniques such as renal denervation, arteriovenous fistulas, and autonomic devices represent novel therapeutic approaches.
- New hypertension guidelines have introduced revised definitions and treatment targets, sparking ongoing debate.
Conclusions:
- Despite effective drug therapies, research continues into novel treatments, including neuroendocrine modulation via drugs and devices.
- The goal of these new treatments is to further enhance hypertension management and decrease cardiovascular events.
- Continuous innovation is essential for improving patient outcomes in hypertension care.
Background:
This article summarizes the emerging field of hypertension over the last decades. It covers paradigm shifts on hypertension from an undefined cardiovascular condition to the most relevant cardiovascular modifiable risk factor and the developments of drug treatments and interventional treatments to improve cardiovascular outcomes.
Methods:
We performed a selective literature research in PubMed on trials published in the past until 2018 without time restrictions and covered unpublished trials disclosed in ClinicalTrials.org.
Results:
The development of treatments of hypertension is a success story covering many decades from the early attempts with drug treatments, development of tolerable and effective medications to interventional techniques involving renal denervation, AV fistulas, and autonomic devices. Novel guidelines define new definitions and treatment targets of hypertension, which are a matter of ongoing discussion.
Conclusion:
Despite the development of tolerable and effective drugs, new treatments in the field of neuroendocrine modulation by drugs and devices are still under development trying to further improve treatment of patients with hypertension and to further reduce cardiovascular events in those individuals.
More Related Videos
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
07:10At-Risk Butterfly Captive Propagation Programs to Enhance Life History Knowledge and Effective Ex Situ Conservation Techniques
Published on: February 11, 2020
Related Concept Videos
What is Evolutionary History?
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Life Histories
History of Microbiology